Butabarbital decreases consequences of sufentanil SL by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of CYP3A4 inducers may decrease sufentanil ranges and efficacy, probably precipitating withdrawal syndrome in patients that have created Bodily dependence to sufentanil. Discontinuation of concomitantly utilised CYP3A4 inducers... https://audreyz575ozh3.eedblog.com/profile